Jan 28 (Reuters) - Regeneron Pharmaceuticals Inc and its partner Sanofi said on Friday they voluntarily withdrew their application with the U.S. health regulator for additional use of anti-cancer drug Libtayo as second-line treatment for patients with advanced cervical cancer. (Reporting by Leroy Leo; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,086 USD | -0.86% | +1.35% | +23.61% |
07-12 | UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating | MT |
07-11 | Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.61% | 117B | |
+20.03% | 126B | |
+22.82% | 27.52B | |
-18.07% | 20.87B | |
-14.48% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B | |
+143.76% | 12.18B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron, Sanofi withdraw FDA application for Libtayo use in cervical cancer